Lidocaine Spray Plus Oral Celecoxib for Pain Control During Hysterosalpingography
NCT ID: NCT04505657
Last Updated: 2021-09-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
150 participants
INTERVENTIONAL
2020-09-01
2021-09-27
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Lidocaine Patch Versus Intravenous Lidocaine in Pain Relief After Laparoscopy
NCT04506034
Lidocaine Infusion On Hysteroscopic Media Versus Oral Diclofinac For Pain Relief During Outpatient Hysteroscopy
NCT03298646
Intracervical Lidocaine Versus Intramuscular Diclofenac for Pain Relief in HSG in a Tertiary Hospital in Kano
NCT02918812
Lidocaine Infusion in Hystroscopy
NCT03825016
"Efficacy of Local Anesthetic for Postoperative Pain in Gynecologic Laparoscopy"
NCT07030647
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Celecoxib plus lidocaine
Celecoxib 200 mg (Celebrex® 200, Pfizer,USA) administered orally 2 h before the procedure +10% lidocaine spray 4 puffs during the procedure
celecoxib plus lidocaine
Celecoxib 200 mg (Celebrex® 200, Pfizer,USA) administered orally 2 h before the procedure +10% lidocaine spray 4 puffs during the procedure
Celecoxib
Celecoxib 200 mg (Celebrex® 200, Pfizer,USA) administered orally 2 h before the procedure +Sterile water 4 puffs during the procedure
Celecoxib
Celecoxib 200 mg (Celebrex® 200, Pfizer,USA) administered orally 2 h before the procedure +Sterile water 4 puffs during the procedure
lidocaine
placebo to celecoxib administered orally 2 h before the procedure +10% lidocaine spray 4 puffs during the procedure
lidocaine
placebo to celecoxib administered orally 2 h before the procedure +10% lidocaine spray 4 puffs during the procedure
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
celecoxib plus lidocaine
Celecoxib 200 mg (Celebrex® 200, Pfizer,USA) administered orally 2 h before the procedure +10% lidocaine spray 4 puffs during the procedure
Celecoxib
Celecoxib 200 mg (Celebrex® 200, Pfizer,USA) administered orally 2 h before the procedure +Sterile water 4 puffs during the procedure
lidocaine
placebo to celecoxib administered orally 2 h before the procedure +10% lidocaine spray 4 puffs during the procedure
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
45 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Aswan University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
hany farouk
A Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
nahla w Shady, md
Role: STUDY_CHAIR
Aswan universirty
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Aswan University Hospital
Aswān, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
aswu/351/5/19
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.